Go or no go? Aducanumab’s day of reckoning
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Go or no go? The FDA plays hardball
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
Fresh antitrust push hits biopharma
Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.
Go or no go? Vaccine panel upstages US approval decisions
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.